BridgeBio Pharma Inc (BBIO) Sector
Health Care

(Current) $27.94
-0.01 (-0.04%) Open Price: 27.94


BridgeBio Pharma Inc. is a biopharmaceutical company that focuses on developing and advancing transformative medicines for patients with genetically driven diseases. Founded in 2015 and headquartered in Palo Alto, California, the company operates with a unique model that combines research, development, and commercialization to address a wide range of rare diseases and genetic disorders.


BridgeBio's core mission is to identify and develop therapies for diseases caused by genetic mutations. The company's approach involves creating a portfolio of subsidiary companies, each focused on a specific disease area, with the goal of rapidly advancing treatments from discovery to clinical development and ultimately commercialization.


One of BridgeBio's distinctive features is its commitment to both internal research and external partnerships. The company collaborates with academic institutions, research organizations, and other biopharmaceutical companies to leverage expertise, technology, and resources in order to accelerate the development of potential therapies.


BridgeBio's portfolio encompasses various therapeutic areas, including oncology, neurology, cardiology, dermatology, and more. The company's innovative pipeline includes investigational drugs that target specific genetic mutations and pathways, aiming to address the underlying causes of diseases rather than just treating symptoms.


The company's subsidiaries, such as Eidos Therapeutics, QED Therapeutics, and Origin Biosciences, work collectively to bring novel therapies to patients. BridgeBio's holistic approach streamlines drug development and maximizes the potential impact on patients' lives.



(05/24/24) $27.94
(05/27/24) $27.95
(05/27/24) (Qty.)970,120
(05/24/24) $27.50
(05/24/24) $28.28
(05/05/24) $27.16
(05/12/24) $31.16
LetsEncrypt SSL Secure Stripe Payment Processing